• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Generic drug shows promise as diabetes vaccine in small, years-long study

June 21, 2018 By Sarah Faulkner

diabetesA cheap, generic tuberculosis vaccine lowered blood glucose levels in nine patients with Type I diabetes and the effects lasted for years, according to a study published this week in npj Vaccines.

The study was conducted at Massachusetts General Hospital by Dr. Denise Faustman – a name that has long been saddled with controversy in the diabetes community, due in large part to a dispute with the JDRF after the organization declined to fund her work.

The study was small. Nine people were given two doses of the vaccine and after several years, their blood sugar levels fell close to expected levels. All of the trial’s participants still use insulin and monitor their glucose, but they reported using less insulin and checking their blood sugar less frequently years after receiving the therapy.

Other researchers in the diabetes community expressed optimism over the study’s results but stressed that more data needs to be collected.

“If what they found is true, they really have something here,” Georgetown University’s Dr. Joseph Bellanti told STAT.

The vaccine, known as Bacillus Calmette-Guerin, works by boosting a patient’s T cells and by influencing the patient’s metabolism so cells gobble up glucose, according to data from preclinical mouse studies. Now, Faustman’s team is gearing up for a 150-patient Phase II study of the potential diabetes therapy.

The BCG vaccine is cheap – it costs less than $1 per dose, according to STAT. That’s part of the reason that it’s been challenging for her lab to attract funding, Faustman told the news outlet.

“Potential funders come [to my lab] and ask, ‘How can we make money off this?'” she said.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Featured, Pharmaceuticals, Research & Development Tagged With: Massachusetts General Hospital

IN CASE YOU MISSED IT

  • Senseonics stock is up as it sticks by revenue guidance
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS